DV
Dividend Vision

PRTA — Prothena Corporation plc

Prothena Corporation plc (PRTA)

Total return is 23.1% over the past 13.6 years, 561.5 points behind SPY at 584.6%. Its deepest 1-year drawdown was 31.3%.

PRTA is an individual stock in the biotechnology sector rather than a diversified ETF, representing a single company focused on neurodegenerative disease research and development. As a single-stock holding, it does not have a defined distribution frequency or yield profile typical of dividend-focused ETFs, and standard ETF metrics like expense ratios and asset under management do not apply. This security appeals primarily to investors seeking direct exposure to a specific biotech company's growth potential rather than those targeting regular dividend income.

PRTA key facts

Asset type
Stock
Asset class
Equity
Inception date
12/21/2012
Last close
$8.86
Market cap
$453,902,560
Average volume
312600.0
Beta
-0.314
Payout ratio
0.0
Forward P/E
10.627
EPS
$-2.82